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ABSTRACT 
Gestational diabetes mellitus (GDM), diabetes diagnosed in the second or third trimester of 
pregnancy that is not clearly overt diabetes, has become more common as the rates of obesity in 
women of childbearing age have increased. Undiagnosed, uncontrolled diabetes in pregnancy 
can lead to maternal and infant health comorbidities as well as have adverse long-term effects for 
mother or baby.  Although routine screening for gestational diabetes mellitus (GDM) occurs 
between 24 and 28 weeks gestation, the American Congress of Obstetricians and Gynecologists 
(ACOG) recommends screening earlier in pregnancy for women at risk for undiagnosed type 2 
diabetes. Risk factors include previous history of GDM, known impaired glucose metabolism, or 
obesity (BMI > 30). The purpose of this project is to implement the clinical practice guideline for 
early maternal glucose screening during pregnancy in women with risk factors through the 
integration of a clinical decision support (CDS) tool in an electronic health record (EHR).  CDS 
tools can be utilized as a point of care strategy to remind providers of the clinical practice 
guidelines and to assist providers in decision-making related to screening. Participating providers 
(n=18) utilized the CDS tool during the initial obstetrical visit for at risk women without a pre-
pregnancy diabetes diagnosis and entering prenatal care prior to 24 weeks. The impact of 
implantation of the CDS tool shows that an increase in screening was statistically significant 
(p<.001). 
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Impact of an Electronic Clinical Decision Support Tool on  
Early Maternal Glucose Screening in Pregnancy  
Up to 9.2% of women who give birth in the United States each year develop diabetes 
during their pregnancy (DeSisto, Kim, & Sharma, 2014). The obesity and diabetes epidemics 
have led to an increase in type 2 diabetes in women of childbearing age, and in the number of 
pregnant women with undiagnosed type 2 diabetes [T2DM] (ADA, 2015). The HAPO study 
revealed that uncontrolled diabetes in pregnancy can lead to adverse maternal and fetal outcomes 
(Metzger, Lowe, Dyer, Trimble, Chaovarindr, Coustan, Hadden, McCance, Hod, McIntyre, Oats, 
Persson, Rogers, & Sacks [HAPO], 2008). Diabetes in pregnancy (DIP) is any form of diabetes 
while pregnant, including GDM, Type 2 DM (T2DM) or insulin resistant diabetes, and Type 1 
DM (T1DM) or insulin-dependent diabetes (Chamberlain, McNamara, Williams, Yore, 
Oldensburg, Oats, & Eades, 2013) Gestational diabetes mellitus (GDM) is diabetes diagnosed in 
the second or third trimester of pregnancy that is not clearly overt diabetes (American Diabetes 
Association [ADA], 2015).When undiagnosed T2DM is recognized, it is later in pregnancy due 
to routine GDM screening protocol and considered to be GDM based on timing of recognition 
(ADA, 2015). In the meantime, because it is unrecognized prior to routine GDM screening, 
undiagnosed type 2 diabetes remains uncontrolled during the first trimester. The impact of 
uncontrolled diabetes on mother and baby can be devastating; however this can be alleviated 
with early maternal glucose screening. While routine screening for gestational diabetes in the 
United States occurs between 24 and 28 weeks gestation, multiple national organizations 
recommend early screening based on maternal risk factors. What constitutes risk factors varies 
with each expert opinion guideline (American Congress of Obstetricians & Gynecologists 
[ACOG], 2014; ADA, 2015; US Preventative Services Task Force [USPSTF], 2014).  
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Background 
 GDM has become more common as the rates of obesity and diabetes mellitus of women 
of childbearing age have increased (Centers for Disease Control & Prevention [CDC], 2014; 
Hillier, Vesco, Whitlock, et al., 2008). It is estimated that there are 13.4 million women 
diagnosed with diabetes; it is projected that one out of three people will develop diabetes in their 
lifetime (CDC, 2014). The increase of diabetes in women is leading to concern for maternal and 
fetal outcomes  
Recent evidence shows that in women with risk factors such as marked obesity, personal 
history of GDM, or glycosuria, early screening is a predictor of gestational diabetes and may be 
an indicator of pre-gestational diabetes (ADA, 2015; Chamberlain, et al., 2013; Corrado, 
D’Anna, Cannata, Interdonato, Pintaudi, & Di Benedetto, 2012; Farah, McGoldrick, Fattah, 
O’Connor, Kennelly, & Turner, 2012; Harrison, et al., 2015; Syngelaki, et al., 2015; & Teede, 
Harrison, Teh, Paul, & Allen, 2011). Routine screening for gestational diabetes  has been 
recommended between 24 and 28 weeks gestation., The American Congress of Obstetricians and 
Gynecologists (ACOG), whose guidelines are most recognized among childbearing care 
providers, recommends screening women at risk for undiagnosed type 2 diabetes as early as the 
first prenatal visit.  
Clinical Significance 
Diabetes in pregnancy can lead to both fetal consequences such as macrosomia, shoulder 
dystocia, neonatal hypoglycemia, and increased neonatal intensive care unit (NICU) admissions, 
as well maternal consequences such as increased risk of preeclampsia and increased risk of 
operative delivery, among other adverse maternal outcomes. The associated longer 
hospitalizations drive up healthcare costs. Additionally, in utero exposure to GDM puts the 
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infant at six times higher risk of later developing impaired glucose tolerance or T2DM (Holder, 
Giannini, Santoro, Pierpont, Shaw, Duran, Caprio, & Weiss, 2014). Mothers are at seven times 
higher risk of developing T2DM later in life (Kim, 2014). The increased risk for mother or baby 
to develop T2DM later in life also contributes to the rising economic impact of diabetes (CDC, 
2014). Earlier screening, diagnosis, and treatment improve perinatal outcomes and long term 
economic effects of diabetes. 
Internal evidence 
The project site is Federally Qualified Health Care (FQHC) in the southwestern United 
States. The interdisciplinary team of eighteen providers includes physicians, nurse practitioners, 
and nurse midwives that care for women across the continuum of pregnancy. Many of the 
women who receive prenatal care met the risk factors for early diabetes screening in pregnancy; 
however, a review of one hundred charts revealed that few women with risk factors were 
screened early for GDM.  
Patients are screened at 24-28 weeks gestation for GDM; those with elevated screenings 
have diagnostic testing approximately one to two weeks later. If t patients had undiagnosed 
T2DM prior to pregnancy, there is potential for 25-30 weeks of unmanaged diabetes in a 40-
week gestational period. Some providers only order early screening for those women who had a 
previous pregnancy with gestational diabetes. The project site lacks a standardized practice 
regarding early screening for diabetes.   
Clinical practice guidelines can be implemented at the point of care through the use of 
electronic clinical decision support (CDS) tools. CDS tools can be imbedded in electronic health 
records (EHR) to assist providers in decision-making related to the application of screening and 
management guidelines. Studies have demonstrated a positive impact of CDS tools on healthcare 
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provider adherence to preventative care recommendations (Jaspers, Smeulers, Vermeulen, & 
Peute, 2011).  
While early screening does not prevent   later diagnosis of gestational diabetes leads to 
initiation of earlier intervention, treatment, and prevention of adverse outcomes (Gabbay-Benziv 
& Baschat, 2015; Nilofer, Raju, Dakshayini, & Zaki, 2012). This has led to the clinically 
relevant PICOT question: “In women with risk factors for GDM, how does early maternal 
glucose screening using an electronic clinical support tool compared to current practice standards 
affect timely diagnoses of diabetes in pregnancy?” 
Search Strategies 
In order to answer this clinical question, an exhaustive search of the literature was carried 
out. The Cochrane Database, CINAHL, and PubMed were searched using the keywords (with 
Boolean connectors) glucose tolerance (and) first trimester. Additional keywords included 
pregnancy, screening, diabetes, gestational diabetes mellitus, GDM, and CDS tool. Searches 
were restricted to peer-reviewed journals written in English and published from 2011 to 2016. 
Abstracts were inspected to determine relevancy to the clinical question. To be considered for 
inclusion, studies were required to have glucose tolerance screening prior to 24 weeks gestation 
as the primary intervention. Exclusion criteria included glucose tolerance screening initiated after 
24 weeks gestation and results that did not pertain to pregnant women with risk factors. 
CINAHL yielded 16 results, with two being chosen for further appraisal. A search under 
the Cochrane Database yielded two reviews, with neither being chosen as appropriate. PubMed 
yielded 43 articles, and ten were selected for review. A total of 12 articles were critically 
examined for level of evidence and clinical relevancy. One randomized controlled trial, two 
retrospective cohort studies, one prospective observational study, and one prospective double-
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blinded randomized study were chosen for inclusion in this review.  
Critical Appraisal and Synthesis 
Evidence shows that in women with risk factors, early screening may identify women 
with pre-gestational diabetes, or those who most likely progress to GDM, thus improving the 
timeliness of diagnosis (Kulaksizoglu, S., Kulaksizoglu, M., Kebapcilar, Torun, Ozcimen, & 
Turkoglu, 2013). The effects of poor glycemic control and length of disease can be devastating 
to both maternal and fetal outcomes (Ballas, Moore, & Ramos, 2011). Those who are diagnosed 
with gestational diabetes early are more likely to require medication for glycemic control, and 
achievement of tighter glycemic control shows a decreased poor perinatal outcomes (Alunni, 
Roeder, Moore, & Ramos, 2015; Reece, 2010). Early screening, diagnosis, and treatment 
correlate to perinatal outcomes, further demonstrating the importance of screening early 
(Neelakandan & Sethu, 2014; Reece, 2010).  
The purpose of a CDS tool built into an EHR is to support delivery of evidence-based 
care and facilitate decision-making (Silvestrin, Steenrod, Coyne, Gross, Esinduy, Kodsi, Slifka, 
Abraham, Araiza, Bushmakin, & Luo, 2015). The use of a CDS tool has been shown to be 
effective in various clinical settings. Valuable areas of improvement include efficient use of 
laboratory services and cost containment, as well as improving early detection of disease 
processes (Algaze, Wood, Pageler, Sharek, Longhurst, & Shin, 2016; Allen, 2012).  It has also 
found to decrease non-essential testing while providing high-quality care and maintaining safety 
(Kharbanda, Madhok, Krause, Vazquez-Benitez, Kharbanda, Mize, & Schmeling, 2016). 
Purpose Statement 
The purpose of this project is to improve timeliness of diagnosis of diabetes in pregnancy 
so that lifestyle changes and necessary treatment can be initiated. A CDS tool in an EHR, 
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implementing the ACOG clinical practice guideline for early maternal glucose screening during 
pregnancy in women with risk factors, facilitates early recognition. Early recognition and 
treatment plays an important role in improving outcomes, and obstetrical providers are vital in 
achieving progress toward the goal of short-term and long-term maternal and fetal health.  
Evidence-Based Practice Model 
  The Stetler Model is a five-step model focused on critical thinking and the use of 
evidence by the practitioner (Schaffer, Sandau, & Diedrick, 2012).  The first step is preparation, 
which was done by assessing the needs of a FQHC in relation to influential factors such as 
patient population and circumstances. Many of these women met the requirements for early 
screening, but where not being screened. The second step is validation through systematically 
searching databases for relevant studies, critiquing them, and summarizing the evidence found in 
each study. The third step, comparative evaluation and decision-making were done by comparing 
the studies with similar interventions and outcomes to determine which would appropriately 
answer the PICOT question and synthesize the data. Part of the decision-making assessed the 
projected process based on the fit of setting, feasibility, the substantiality of evidence, as well as 
current practice in the setting, and determined if it would be possible within the system. It was 
determined it would be more effective to focus on a provider centered project to broaden the 
effects of improved patient outcomes. The fourth step, translation and application, is the net 
process. The net process involves implementing a tool into the EHR developed around ACOG’s 
guidelines for early diabetes in pregnancy screening and collecting data surrounding the tool 
usage. Once this step was completed, the fifth step, evaluation, was done to determine whether 
the PICOT question was appropriately answered and the goals were met. The practice itself will 
evaluate the process to determine if it is sustainable. 
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Contribution of Theory  
 Ferlie and Shortell developed a model for improving quality and outcomes in healthcare 
(Ferlie & Shortell, 2001).  This is done through a multilevel approach containing four levels of 
change, individual healthcare practitioner, the healthcare team, the overall organization, and the 
cultural environment of the organization (Ferlie & Shortell, 2001). The first level is the 
individual practitioner. Utilization of the ACOG guideline based algorithm criteria will serve as a 
reminder to the provider to screen patients for diabetes early in pregnancy if they meet the 
criteria. Healthcare is usually delivered in groups or teams, and a well-functioning team is 
generally associated with higher quality care (Ferlie & Shortell, 2001). In the collaborative care 
clinic in which the project was implemented, involving the healthcare team improved the success 
rate of identifying, screening, and treating those who meet the criteria. For a sustained change, 
the ability of an organization to provide overall climate and cultural change is necessary (Ferlie 
& Shortell, 2001). By obtaining buy-in from the organization, the early screening project was 
possible and has increased potential of being rolled out organization-wide once it has 
successfully commenced. By considering multiple levels, the greatest impact can be achieved 
(Ferlie & Shortell, 2011). 
Project Methods 
After the project received expedited review and approval by the Arizona State University 
IRB on 10/11/2016, it was implemented at the project site. Providers (n=18) from the Women’s 
Health clinics, including nurse practitioners, midwives, and physicians (MD, DO) were recruited 
at a monthly provider meeting. A recruitment/informed consent letter was given to those 
providers interested in participating in the project.. No member has a dual role with the study 
population. 
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Pre Intervention  
The co-investigators and IT specialist worked together to add an Early Gestational 
Diabetes Screening CDS tool to the obstetrical template in the History of Present Illness (HPI) 
section of the EHR. The CDS tool is a drop down style format that integrates the ACOG 
recommendation for early gestational diabetes screening. Patients that qualified for early 
gestational diabetes screening included: BMI>30, GDM in a previous pregnancy, or known 
impaired glucose. If a patient qualified for early screening, the CDS tool provided a prompt for 
the participating provider as a reminder to order early screening. The CDS tool is a system-wide 
change and therefore available for use by all providers regardless of whether they participate in 
the project.  
The co-investigator performed a review of a convenience sample of 20 of the 
participating providers’ records from patients seen within 6 months prior to the intervention for 
baseline performance data.. Eligible patient charts were determined by gestational age of 
pregnancy and the following codes for OB Visit in their patient assessment: Z34.01, Z34.02, 
Z34.81, Z34.82, O09.5, O09.521, O09.522, and Z3A.10-Z3A.23. These records were further 
stratified based on assignment as a “New OB Visit”.  Records of patients with a pre-pregnancy 
diagnosis of diabetes (T1DM or T2DM) were excluded. The chart audit form was developed by 
the co-investigator and face validity was confirmed by 10 reviewers, three ASU faculty, one 
being an experience women’s health nurse practitioner and the other two are experienced family 
nurse practitioners, four peers in the women’s health nurse practitioner program, and three 
healthcare providers, one an experienced women’s health nurse practitioner, one experienced 
obstetrician & gynecologist, and one experienced family nurse practitioner in a federally 
qualified health canter. 
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Intervention 
Participating providers received training during a 15 minute session by the co-
investigator, at a women’s health provider meeting or at an individual meeting, on early 
screening recommendations for gestational diabetes and the new electronic CDS tool in the EHR. 
The participants were given a hard copy of the Early Screening for GDM Algorithm for 
reference. 
Participating providers were able to utilize the new CDS tool in the EHR system during 
the initial obstetrical visit for women entering prenatal care prior to 24 weeks gestation and who 
do not have a pre-pregnancy diagnosis of diabetes. Participating providers were sent electronic 
reminder messages approximately once per month encouraging use of the CDS tool.  
Post Intervention 
The co-investigator performed a post intervention review of 20 of the participant 
provider's patient charts using the same criteria as in the pre-intervention chart audit. This 
process determined rate of early screening for gestational diabetes in patients with risk factors, 
documentation of electronic CDS tool use, and referral to the registered dietician.  
Cost 
There was no additional cost for screening because all required GDM screening is 
included in the obstetrical package. There were negligible costs for IT integration, as the IT 
specialist is a full time employee of the site and did not require more than 15 minutes to integrate 
the data into the EHR system. Long term use of the CDS tool will incur no additional costs.  
Outcomes 
 Eighteen providers were educated on the guidelines and tool usage. However, only six 
providers used the screening tool. A chi-squared test was  performed for both providers who used 
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the tool and all providers combined. The outcome was measured through increase in percentage 
of patients with risk factors that were screened at the first prenatal visit or in the first trimester of 
pregnancy, both with and without tool usage, and increased percentage of patients diagnosed 
early with diabetes in pregnancy referred to a registered dietician for diabetic diet education and 
management.   
All Providers 
 A total of 489 charts were reviewed, 244 pre-implementation charts and 245 post-
implementation charts. Up to 20 charts per provider were reviewed over a six month period prior 
to implementation, and up to 20 charts per provider were reviewed over the three month period 
following implementation. Some providers had less than 20 cases during each of these time 
periods, with one provider not having any charts meeting criteria. Of the 244 pre-implementation 
charts, 110 qualified for screening, but only 13 (12%) were screened, five of which went on for 
diagnostic testing. Of those five, four of those were diagnosed early with GDM and two of the 
four diagnosed were referred to a dietician. Post-implementation, 151 qualified for screening and 
46 (30%) were screened. Of those 46 screened, 15 went on for diagnostic testing. Ten of the 15 
were diagnosed early with GDM, with six of the 10 being referred to a dietician. Screening 
increase was statistically significant (p=<.001). Diagnosis increase (p=.067) and referral rate 
(p=.594) were not statistically significant. 
Providers Using CDS Tool 
 The results were then run to only include the six (33%) providers who used the CDS tool 
as guidance. A total of 224 charts were reviewed, 105 pre-implementation and 119 post-
implementation charts. Of 105 cases audited, 58 qualified for screening based on ACOG criteria. 
Of those 58, 11(19%) were screened. Of the 11 screened, 4 went on for diagnostic testing and 3 
ELECTRONIC CDS TOOL AND EARLY GDM SCREENING  13 
 
were diagnosed early with GDM in this pregnancy. Of the three diagnosed, only one was 
referred to the Registered Dietician. Post-implementation, 61 qualified for screening based on 
ACOG criteria. Of those 61, 30 (49%) were screened, 26 (87%) of which the CDS tool was used. 
Of the 30 screened, 12 underwent diagnostic testing and 8 were diagnosed early with GDM in 
this pregnancy. Three of those diagnosed had GDM in a previous pregnancy and five met ACOG 
criteria for screening with obesity. Of the eight diagnosed, in seven of them, the CDS tool was 
used, and five were referred to a registered dietician. Screening increase was statistically 
significant (p<.001). Screening with tool usage was statistically significant (p=.001). Diagnosis 
increase (p=.635), diagnosis with tool usage (p=.002), and referral rate (p=.424) were not 
statistically significant.  
Discussion 
 This project was implemented as a system change. Once the CDS tool was embedded in 
the EHR, it is fully functional and no further costs need be incurred in maintaining the tool, 
making it sustainable. Limitations of this project included the small number of providers willing 
to use the CDS tool. Additionally, there was low consistency of use for those who did use it 
(40.3%). Compliance improved after email reminders were sent out, but dropped off after a short 
time. However, there were increases in screening numbers following education and distribution 
of the algorithm whether the screening tool was used or not used. Recommendations for future 
implementation would be to start in a single clinic rather than a system of clinics or obtain buy-in 
by all providers for improved tool usage. An additional recommendation would be to implement 
a site-based project champion and organizational change champion. These two forms of 
champions complement each other to best implement and sustain organizational diabetes 
improvements (Shaw, Howard, West, Crabtree, Nease, Tutt, & Nutting, 2012). 
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Conclusion and Implication 
 Diabetes, including gestational diabetes mellitus, is a rising problem in the United States. 
In addition to increased diabetes in pregnancy, there are women who become pregnant unaware 
that they have diabetes and who are diagnosed during pregnancy. Both women with gestational 
diabetes and infants of those women are at increased risk of both short term and long term 
complications associated with diabetes. There is a large economic impact due to the cost of 
treating the related morbidities in addition to the morbidities themselves.  
Nurse practitioners play an essential role in screening and educating patients about their 
health risks and management of diabetes in pregnancy. Early screening for undetected diabetes is 
associated with prompt diagnosis and treatment initiation. A point of care CDS tool can improve 
provider adherence to clinical practice guidelines for early maternal glucose screening during 
pregnancy. Additionally, use of a site champion team including a nurse practitioner, physician, 
and medical assistant may improve implementation success of a CDS tool and early screening 
follow through.  
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